7th BioVaria Attracts Leading Life-Science Innovators
5/9/2014 9:38:19 AM
9 May 2014, Munich, Germany – On 6 May 2014, decision makers from the biopharmaceutical and medtech industries gathered in Munich with leading scientists and technology transfer professionals to learn about the hottest life-science innovations from universities and research institutes across Europe and initiate co-development partnerships. Altogether, 140 participants joined the event.
The conference, organized by Ascenion and ten further technology transfer organizations, featured a total of 40 licensing opportunities: diagnostic and therapeutic projects as well as platform technologies. New partners such as IOCB TTO from Prague, Czech Republic, gave new impulses that were well received from industry.
‘The technologies presented perfectly matched the participants’ inlicensing needs,’ Dr Christian Stein, CEO of Ascenion comments. ‘There are many more high-potential partners in Eastern Europe and other European regions that have so far received little recognition. For 2015, we will work to attract as many of them as possible as BioVaria partners.’
Four industry leaders, Bayer Pharma, Boehringer Ingelheim, Johnson & Johnson Innovation and MSD, also presented their inlicensing needs.
‘There are two things that make BioVaria stand out from the crowd of partnering events: the breadth and quality of the technologies presented and the interactive and familiar atmosphere,’ said Dr Heinz Schwer, Senior Director Corporate Finance & Corporate Development at MorphoSys.
The next BioVaria, featuring the biennial Spin-off Panel, will take place on 11 May 2015 in Munich.
For further information and a full list of technologies presented during BioVaria 2014 visit www.biovaria.org.
BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical and medtech industry.
Key features of BioVaria 2014:
- Unique gathering of Europe's top scientists, technology transfer professionals and industry representatives.
- Presentation of licensable technologies originating from a broad range of research institutes and universities across Europe.
- Focus on patent-protected, commercially attractive opportunities covering research tools, medical device technologies, diagnostics and therapeutics in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas.
- Interactive, efficient one-day format combining 10-min oral presentations with an all-day poster exhibition.
- Ample space to discuss scientific details face-to-face with the inventors.
- Jointly organized by Ascenion and a selected group of leading technology transfer organizations.
Bavarian Ministry of Economic Affairs and Media, Energy and Technology
BioM, Bayer HealthCare, Boehringer Ingelheim, Johnson & Johnson Innovation, MSD, HERTIN, Sanofi, Vossius & Partner
Technology transfer partners:
Ascenion, Austria Wirtschaftsservice Gesellschaft, Bayerische Patentallianz, BTO Bergen Teknologioverføring, EMBLEM Technology Transfer, FIST, IOCB TTO, Lead Discovery Center, Max Planck Innovation, MRC Technology, PROvendis
Forum MedTech Pharma; LifeScience Nord
ASTP-Proton, BIO Deutschland, Business Wire, Current Partnering, GoingPublic, Iptechex / Pharmalicensing, KONOCOM, transkript
Ascenion GmbH is an IP asset management company with particular expertise in the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the LifeScience Foundation for the Promotion of Science and Research and has since acquired 23 research institutes in the Helmholtz and Leibniz Associations, together with the Charité, the Hannover Medical School, the Universität zu Lübeck and the research institute TWINCORE as partners. Ascenion currently markets around 750 technologies on behalf of these institutes, and closes an average of about 80 revenue-generating agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth and Ascenion holds equity in 24 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg.
Dr. Susanne Letzelter, Corporate Development & Communication
T: +49 (0)89 318814-16, E: firstname.lastname@example.org
Ascenion GmbH, Herzogstraße 64, 80803 München
Help employers find you! Check out all the jobs and post your resume.
comments powered by